ADPKD patients have a more severely impaired maximal urine concentrating capacity with a lower maximal achieved urine urea concentration in comparison to IgAN controls with similar endogenous copeptin and AVP responses. The gene discussed is AVP; the disease is autosomal dominant polycystic kidney disease.